PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Bayer logo

Bayer

Status

Completed

Conditions

Diagnostic Imaging

Treatments

Drug: Ultravist (Iopromide, BAY86-4877)

Study type

Observational

Funder types

Industry

Identifiers

NCT00876083
13276
14480
14376
13422
14181
UV0701
14692
14337
13859
14338
14527
14586
13421
13275
14243
14661
14528
14336
14245
14180
13212
14526
13602

Details and patient eligibility

About

The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.

Enrollment

44,920 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Exclusion criteria

  • No exclusion criteria besides the contraindications for the use of Ultravist as mentioned in the product information.

Trial design

44,920 participants in 1 patient group

Group 1
Treatment:
Drug: Ultravist (Iopromide, BAY86-4877)

Trial contacts and locations

21

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems